This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
Nature Communications Open Access 11 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. New class PCSK9 blockers stride into cholesterol market. Nat Biotechnol 33, 785–786 (2015). https://doi.org/10.1038/nbt0815-785
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0815-785
This article is cited by
-
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
Nature Communications (2017)
-
Amgen cholesterol antibody feud could kill key IP rule
Nature Biotechnology (2017)
-
Pfizer drops phase 3 lipid-lowering antibody
Nature Biotechnology (2016)
-
AbbVie buys last available priority voucher for $350 million
Nature Biotechnology (2015)